DSIP Peptide Dosage, How Much and When to Take It

DSIP Peptide Dosage: What Dose Did Human Studies Use?

DSIP peptide dosage in published human sleep trials was 25 nmol/kg, given intravenously (into a vein). For a 90 kg man, that comes to about 1.9 mg, or 1,900 micrograms (mcg). The sleep trials ran from a single dose up to four nights in a row. No clinical study has tested injection under the skin.

If you're researching this compound, I've linked a trusted source on the recommended sources page. It supports the channel.

DSIP (delta sleep-inducing peptide) is a nine-amino-acid peptide. That means it is a short chain of the building blocks of protein. It was first isolated from rabbit blood in 1977. The human evidence base is small. An FDA review counted 209 people who received it through a vein, at 25 to 150 nmol/kg, for 1 to 15 days. That count also includes studies of drug and alcohol withdrawal. The same review found no clinical study of injection under the skin (FDA 2026). That gap between the lab and the forum matters, so we walk through it below.

What Was the DSIP Peptide Dosage Protocol in Clinical Trials?

The DSIP peptide dosage protocol in the controlled sleep studies used one dose: 25 nmol/kg of bodyweight. A nanomole is a tiny unit of amount, one billionth of a mole. Every dose went into a vein. The studies differ in timing, length and results, so here is each one in turn.

Schneider-Helmert and Schoenenberger gave a single 25 nmol/kg dose through a vein to six middle-aged people with chronic insomnia. Sleep got longer, with fewer interruptions. The effect began only in the second hour after the injection. In the first hour there was a slight arousing effect. The sleep effect lasted up to six hours of night sleep. The authors saw no daytime sedation or other side effects (Schneider-Helmert 1981).

Monti and colleagues gave the same dose or a placebo through a vein during four nights. This was a double-blind crossover trial with people who had insomnia. Night-time awakenings and the time to fall into non-REM sleep went down on DSIP. Yet these changes were not significant against baseline or placebo nights. Total sleep time rose, but only through light stage 2 sleep. Slow-wave sleep, the deep stages 3 and 4, did not change. The authors judged the sleep gain to be of little clinical significance (Monti et al. 1987).

Bes and colleagues studied 16 people with chronic insomnia in a sleep laboratory. Each person slept there for five nights in a row. Half got 25 nmol/kg of DSIP through a vein in the afternoon before nights 3, 4 and 5. The other half got a glucose placebo. The DSIP group showed higher sleep efficiency, meaning more time in bed spent asleep. They also fell asleep faster than the placebo group. Sleep was measured with a full overnight recording of brain waves. But the authors called these effects weak. Part of the gap may have come from a chance change in the placebo group. How well people felt they slept did not change. They concluded that short-term DSIP is not likely to bring major benefit in chronic insomnia (Bes et al. 1992).

A later summary by Schneider-Helmert pulled together several studies of 25 nmol/kg shots. Two studies found better sleep after single injections before sleep. Repeated doses seemed to build up, with sleep structure normalising after four doses. Repeated morning injections still helped night sleep. Two doses a day did not (Schneider-Helmert 1984).

How Much Is the DSIP Peptide Dosage for Sleep in Milligrams?

The DSIP peptide dosage for sleep in the trials was set per kilogram, so the total depends on bodyweight. Here is the math for a 90 kg man. First, 25 nmol/kg times 90 kg is 2,250 nanomoles. DSIP has a molecular weight of about 849, so one nanomole weighs about 849 nanograms. Then, 2,250 times 849 nanograms is about 1.9 million nanograms. That is about 1.9 mg, or roughly 1,900 mcg. FDA's own figure agrees: it lists 25 nmol/kg as 21.4 mcg per kg (FDA 2026).

DSIP also breaks down fast. FDA's review describes a very short half-life, measured in minutes. Enzymes in the blood cut it into smaller pieces (FDA 2026). Even so, the 1981 trial saw sleep effects that began in the second hour and lasted for hours (Schneider-Helmert 1981). How a short-lived peptide could do that is still an open question.

Animal work hints at where DSIP may act. In female rats, 1 to 5 micrograms injected into a fluid space in the brain raised a reproductive hormone called LH within 30 minutes. Pituitary cells in a dish did not respond. Tissue from the hypothalamus, the brain's hormone control centre, did respond (Iyer and McCann 1987). A 2024 mouse study tested a DSIP fusion peptide built to cross into the brain. It found shifts in serotonin, glutamate, dopamine and melatonin in an insomnia model (Mu et al. 2024). Neither study tells us a human dose.

What About DSIP Peptide Injection Dosage Under the Skin?

There is no tested DSIP peptide injection dosage for use under the skin. FDA looked for clinical studies of this route, called subcutaneous injection, and found none. It also found no safety data for it. Every human dose on record went into a vein (FDA 2026).

FDA's review did describe what is sold online. It found clinics and online retailers marketing DSIP injections and nasal sprays. Some offer 5 mg vials of dry powder meant to be mixed with sterile water (FDA 2026). The mixing math is simple division. A 5 mg vial mixed with 3 mL of liquid holds about 1.67 mg per mL. The same vial mixed with 5 mL holds 1 mg per mL. That 1 mg per mL strength is the one FDA evaluated for injection under the skin. Note that the 1.9 mg trial figure above comes from a vein dose. Nobody has shown that it carries over to the skin.

Forums and community sites also share their own microgram amounts for injection under the skin. We could not trace those figures to any trial. They are unverified reports, so we do not list them as a dose.

Vial contents are a separate question from dose. Our guide on how to know if peptides are real covers that. So does our breakdown of how peptide testing labs test purity.

DSIP Peptide Dosage Chart

The DSIP peptide dosage chart below separates what was tested in a clinic from what is shared online. Every tested dose was 25 nmol/kg through a vein, for one to four nights. No row for injection under the skin has trial data behind it.

The chart shows a clear gap. Nobody has run a controlled trial of DSIP under the skin. Any figure shared for that route comes from forum reports with no peer-reviewed data behind it.

What Side Effects Came With the DSIP Peptide Dosage in Trials?

At the 25 nmol/kg DSIP peptide dosage, the sleep trials reported few problems. The 1981 trial saw no daytime sedation or other side effects (Schneider-Helmert 1981). In the Bes trial, one measure of tiredness went down in the DSIP group (Bes et al. 1992).

FDA's review gives a wider view. In the insomnia studies, vein doses were well tolerated with no significant side effects. In a study of drug and alcohol withdrawal, some people had sweating, headache, nausea or dizziness. Two had a drop in blood pressure at the first injection. FDA noted that withdrawal itself makes these reports hard to read. FDA's adverse event database held zero reports for DSIP. FDA also flagged a possible immune reaction to injected peptides, partly from clumping or impurities (FDA 2026).

One trial in 11 healthy men found DSIP cut ACTH, a stress hormone signal from the pituitary gland, for at least three hours. Cortisol levels did not change (Bjartell et al. 1989).

How Does DSIP Peptide Dosage Compare to Melatonin and Magnesium?

DSIP peptide dosage data come from small vein-dose trials in sleep labs. Melatonin and magnesium are taken by mouth and have larger bodies of research. A review of 19 melatonin trials with 1,683 people found modest gains. Melatonin cut the time to fall asleep by about 7 minutes and added about 8 minutes of sleep (Ferracioli-Oda et al. 2013). A review of three magnesium trials in 151 older adults found people fell asleep about 17 minutes faster. The authors rated that evidence low to very low in quality (Mah and Pitre 2021). We found no trial that tested DSIP head to head with either one, or combined with them.

Is There an Official DSIP Peptide Recommended Dosage?

No agency has set a DSIP peptide recommended dosage. DSIP is not part of any FDA-approved drug (FDA 2026). FDA lists it under the name emideltide. On July 24, 2026, an FDA advisory panel on compounding met to discuss it. The question was whether pharmacies may use it as a raw ingredient in compounded drugs. FDA reviewed it for opioid withdrawal, chronic insomnia and narcolepsy (FDA meeting page 2026). FDA's briefing for that meeting concluded that the evidence weighs against adding it to that list. FDA said it would make no final decision until the committee's input and all reviews were done (FDA 2026). Want to see how a dosing table looks once a compound has an approved path? See our tesamorelin dosage protocol piece.

Bibliography

Schneider-Helmert D, Schoenenberger GA. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia. 1981. PubMed 7028502.

Monti JM, Debellis J, Alterwain P, Pellejero T, Monti D. Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. Int J Clin Pharmacol Res. 1987. PubMed 3583493.

Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992. PubMed 1299794.

Schneider-Helmert D. DSIP in insomnia. Eur Neurol. 1984. PubMed 6391925.

Bjartell A, Ekman R, Bergquist S, Widerlöv E. Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man. Psychoneuroendocrinology. 1989. PubMed 2554357.

Iyer KS, McCann SM. Delta sleep inducing peptide (DSIP) stimulates the release of LH but not FSH via a hypothalamic site of action in the rat. Brain Res Bull. 1987. PubMed 3121137.

Mu X, Qu L, Yin L, Wang L, Liu X, Liu D. Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Front Pharmacol. 2024. PMC11498945.

Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013. PubMed 23691095.

Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a Systematic Review and Meta-Analysis. BMC Complement Med Ther. 2021. PubMed 33865376.

US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: Emideltide-Related Bulk Drug Substances. fda.gov/media/193344.

US Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov meeting page.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.